Effect of Qingfei Shenshi Decoction （清肺渗湿汤） Combined with Western Medicine on Clinical Effectiveness and Immune Function for Patients with Bronchial Asthma of Heat Wheezing Syndrome
10.13288/j.11-2166/r.2026.01.007
- VernacularTitle:清肺渗湿汤联合西医治疗对支气管哮喘热哮证患者临床疗效及免疫功能的影响
- Author:
Ying SUN
1
;
Haibo HU
1
;
Na LIU
1
;
Fengchan WANG
1
;
Jinbao ZONG
1
;
Ping HAN
1
;
Peng LI
1
;
Guojing ZHAO
1
;
Haoran WANG
2
;
Xuechao LU
1
Author Information
1. Qingdao Traditional Chinese Medicine Hospital （Qingdao Hiser Hospital），Qingdao，266033
2. First Clinical Medical College，Shandong University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
bronchial asthma;
heat wheezing syndrome;
Qingfei Shenshi Decoction （清肺渗湿汤）;
immune function;
T-lymphocyte subsets;
inflammatory factors
- From:
Journal of Traditional Chinese Medicine
2026;67(1):38-44
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical effectiveness and safety of Qingfei Shenshi Decoction （清肺渗湿汤） combined with western medicine for patients with bronchial asthma of heat wheezing syndrome， and to explore its potential mechanism of action. MethodsEighty-six participants with bronchial asthma of heat wheezing syndrome were randomly divided into treatment group and control group， each group with 43 participants. The control group received conventional western medicine， and the treatment group was additionally administered Qingfei Shenshi Decoction orally on the basis of the control group， 1 dose per day. Both groups were treated for 14 days. The primary outcome measure was clinical effectiveness； secondary outcome measures included traditional Chinese medicine （TCM） syndrome score， asthma control test （ACT） score， pulmonary function indices such as forced expiratory volume in 1 second （FEV1）， forced vital capacity （FVC）， peak expiratory flow （PEF）， serum inflammatory factor levels including interleukin-4 （IL-4）， tumour necrosis factor-α （TNF-α）， and high-sensitivity C-reactive protein （hs-CRP）， and immune function indices including CD3+， CD4+， CD8+， CD4+/CD8+. All outcome measures were evaluated before and after treatment. Vital signs were monitored， and electrocardiography， blood routine， urine routine， liver function， and renal function tests were performed before and after treatment. Adverse events and reactions during the study were recorded. ResultsA total of 80 patients completed the trial with 40 in each group. The total clinical effective rate of the treatment group was 97.5% （39/40）， which was significantly higher than that of the control group （85.0%， 34/40， P＜0.05）. After treatment， both groups showed decreased TCM syndrome scores， IL-4， TNF-α， hs-CRP， and CD8+ levels， as well as increased ACT scores， CD3+， CD4+， CD4+/CD8+， FEV1， FVC， and PEF levels （P＜0.05 or P＜0.01）. Moreover， the improvements in these indices were more significant in the treatment group than in the control group （P＜0.05 or P＜0.01）. No significant abnormalities in safety indicators were observed in either group， and no adverse events or reactions occurred. ConclusionQingfei Shenshi Decoction combined with conventional western medicine for patients with bronchial asthma of heat wheezing syndrome can effectively improve the clinical symptoms， pulmonary function， and clinical effectiveness， with good safety. Its mechanism may be related to reducing inflammatory factor levels and regulating T lymphocyte subsets to improve immune function.
